Oncovir, Inc is a pharmaceutical corporation dedicated to the development of
nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.
Oncovir promotes Hiltonol (poly-ICLC) as an experimental viral
mimic and broad activator of innate immunity. While initially developed as an interferon inducer, Hiltonol has much broader
biological effects in humans, including specific antiviral, immune activating, vaccine adjuvant, and antitumor actions.